ESR1 and endometrial cancer: In a study of 763 patients with endometrial cancer, tumors with abnormal expression of p53, L1CAM (cutoff 10%), ER, and PR showed the worst outcome, but in multivariate analysis, L1CAM retained only marginal significance [63].